Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
14.70
+0.48 (3.38%)
At close: Jun 6, 2025, 4:00 PM
14.60
-0.10 (-0.68%)
After-hours: Jun 6, 2025, 5:18 PM EDT
Denali Therapeutics Stock Forecast
Stock Price Forecast
According to 13 professional analysts, the 12-month price target for Denali Therapeutics stock ranges from a low of $24 to a high of $45. The average analyst price target of $33.85 forecasts a 130.27% increase in the stock price over the next year.
Price Target: $33.85 (+130.27%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Denali Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 8 | 8 | 7 | 7 |
| Buy | 5 | 5 | 7 | 7 | 7 | 7 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 16 | 16 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Strong Buy Maintains $28 → $27 | Strong Buy | Maintains | $28 → $27 | +83.67% | May 19, 2025 |
| Baird | Baird | Buy Maintains $30 → $29 | Buy | Maintains | $30 → $29 | +97.28% | May 8, 2025 |
| Wedbush | Wedbush | Buy Maintains $32 → $30 | Buy | Maintains | $32 → $30 | +104.08% | May 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $80 → $32 | Strong Buy | Maintains | $80 → $32 | +117.69% | May 7, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $30 → $28 | Strong Buy | Maintains | $30 → $28 | +90.48% | Mar 10, 2025 |
Financial Forecast
Revenue This Year
31.95M
Revenue Next Year
113.98M
from 31.95M
Increased by 256.73%
EPS This Year
-3.05
from -2.57
EPS Next Year
-2.84
from -3.05
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 145.1M | 298.3M | 820.0M | ||
| Avg | 32.0M | 114.0M | 276.6M | ||
| Low | n/a | 9.4M | 105.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 833.7% | 619.4% | ||
| Avg | - | 256.7% | 142.7% | ||
| Low | - | -70.7% | -7.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.08 | -1.61 | -0.96 | ||
| Avg | -3.05 | -2.84 | -2.42 | ||
| Low | -3.54 | -3.69 | -3.24 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.